Felicitex Therapeutics

Felicitex Therapeutics, Inc. is a preclinical oncology drug development company focused on creating treatments for dormant and proliferative cancers to enhance therapeutic outcomes and long-term results in the most lethal and treatment-resistant liquid and solid tumors (hematologic, ovarian, pancreatic, colorectal, osteosarcoma, lung). The company has designed and patented small molecules and related approaches to selectively disrupt dormant cancer cells in a disease- and tissue context-specific manner. This approach is lethal to cancer cells that rely on cell cycle dysregulation for survival and has been shown to reverse acquired resistance mechanisms. The company’s drug candidates are intended to be effective across a broad range of solid tumors and blood cancers.